{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T00:19:30Z","timestamp":1775607570442,"version":"3.50.1"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2010,8,10]],"date-time":"2010-08-10T00:00:00Z","timestamp":1281398400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2010,10]]},"DOI":"10.1007\/s00228-010-0879-1","type":"journal-article","created":{"date-parts":[[2010,8,9]],"date-time":"2010-08-09T10:48:35Z","timestamp":1281350915000},"page":"977-985","source":"Crossref","is-referenced-by-count":53,"title":["Oxycodone concentrations are greatly increased by the concomitant use of ritonavir or lopinavir\/ritonavir"],"prefix":"10.1007","volume":"66","author":[{"given":"Tuija H.","family":"Nieminen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nora M.","family":"Hagelberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teijo I.","family":"Saari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mikko","family":"Neuvonen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pertti J.","family":"Neuvonen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kari","family":"Laine","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Klaus T.","family":"Olkkola","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2010,8,10]]},"reference":[{"key":"879_CR1","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1016\/j.jpainsymman.2009.05.013","volume":"38","author":"KA Lee","year":"2009","unstructured":"Lee KA, Gay C, Portillo CJ, Coggins T, Davis H, Pullinger CR, Aouizerat BE (2009) Symptom experience in HIV-infected adults: a function of demographic and clinical characteristics. J Pain Symptom Manage 38:882\u2013893","journal-title":"J Pain Symptom Manage"},{"key":"879_CR2","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/S0885-3924(00)00140-8","volume":"19","author":"LM Frich","year":"2000","unstructured":"Frich LM, Borgbjerg FM (2000) Pain and pain treatment in AIDS patients: a longitudinal study. J Pain Symptom Manage 19:339\u2013347","journal-title":"J Pain Symptom Manage"},{"issue":"Suppl 1","key":"879_CR3","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1016\/j.pain.2007.10.009","volume":"132","author":"G Gray","year":"2007","unstructured":"Gray G, Berger P (2007) Pain in women with HIV\/AIDS. Pain 132(Suppl 1):S13\u2013S21","journal-title":"Pain"},{"key":"879_CR4","doi-asserted-by":"crossref","first-page":"325","DOI":"10.2165\/00023210-200519040-00005","volume":"19","author":"S Verma","year":"2005","unstructured":"Verma S, Estanislao L, Simpson D (2005) HIV-associated neuropathic pain: epidemiology, pathophysiology and management. CNS Drugs 19:325\u2013334","journal-title":"CNS Drugs"},{"key":"879_CR5","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1093\/rheumatology\/ken132","volume":"47","author":"UA Walker","year":"2008","unstructured":"Walker UA, Tyndall A, Daikeler T (2008) Rheumatic conditions in human immunodeficiency virus infection. Rheumatology (Oxford) 47:952\u2013959","journal-title":"Rheumatology (Oxford)"},{"key":"879_CR6","doi-asserted-by":"crossref","first-page":"b3002","DOI":"10.1136\/bmj.b3002","volume":"339","author":"R Freynhagen","year":"2009","unstructured":"Freynhagen R, Bennett MI (2009) Diagnosis and management of neuropathic pain. BMJ 339:b3002","journal-title":"BMJ"},{"key":"879_CR7","doi-asserted-by":"crossref","first-page":"S47","DOI":"10.1016\/j.jpainsymman.2005.01.010","volume":"29","author":"E Kalso","year":"2005","unstructured":"Kalso E (2005) Oxycodone. J Pain Symptom Manage 29:S47\u2013S56","journal-title":"J Pain Symptom Manage"},{"key":"879_CR8","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1111\/j.1365-2125.1992.tb04090.x","volume":"33","author":"R P\u00f6yhi\u00e4","year":"1992","unstructured":"P\u00f6yhi\u00e4 R, Sepp\u00e4l\u00e4 T, Olkkola KT, Kalso E (1992) The pharmacokinetics and metabolism of oxycodone after intramuscular and oral administration to healthy subjects. Br J Clin Pharmacol 33:617\u2013621","journal-title":"Br J Clin Pharmacol"},{"key":"879_CR9","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1124\/dmd.32.4.447","volume":"32","author":"B Lalovic","year":"2004","unstructured":"Lalovic B, Phillips B, Risler LL, Howald W, Shen DD (2004) Quantitative contribution of CYP2D6 and CYP3A to oxycodone metabolism in human liver and intestinal microsomes. Drug Metab Dispos 32:447\u2013454","journal-title":"Drug Metab Dispos"},{"key":"879_CR10","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1002\/jps.20327","volume":"94","author":"E Bostr\u00f6m","year":"2005","unstructured":"Bostr\u00f6m E, Simonsson US, Hammarlund-Udenaes M (2005) Oxycodone pharmacokinetics and pharmacodynamics in the rat in the presence of the P-glycoprotein inhibitor PSC833. J Pharm Sci 94:1060\u20131066","journal-title":"J Pharm Sci"},{"key":"879_CR11","doi-asserted-by":"crossref","first-page":"2494","DOI":"10.1002\/jps.20893","volume":"96","author":"HE Hassan","year":"2007","unstructured":"Hassan HE, Myers AL, Lee IJ, Coop A, Eddington ND (2007) Oxycodone induces overexpression of P-glycoprotein (ABCB1) and affects paclitaxel\u2019s tissue distribution in Sprague Dawley rats. J Pharm Sci 96:2494\u20132506","journal-title":"J Pharm Sci"},{"key":"879_CR12","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1124\/dmd.106.009746","volume":"34","author":"E Bostr\u00f6m","year":"2006","unstructured":"Bostr\u00f6m E, Simonsson US, Hammarlund-Udenaes M (2006) In vivo blood-brain barrier transport of oxycodone in the rat: indications for active influx and implications for pharmacokinetics\/pharmacodynamics. Drug Metab Dispos 34:1624\u20131631","journal-title":"Drug Metab Dispos"},{"key":"879_CR13","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1002\/jps.20632","volume":"95","author":"HH Villesen","year":"2006","unstructured":"Villesen HH, Foster DJ, Upton RN, Somogyi AA, Martinez A, Grant C (2006) Cerebral kinetics of oxycodone in conscious sheep. J Pharm Sci 95:1666\u20131676","journal-title":"J Pharm Sci"},{"key":"879_CR14","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1124\/dmd.108.022087","volume":"36","author":"T Okura","year":"2008","unstructured":"Okura T, Hattori A, Takano Y, Sato T, Hammarlund-Udenaes M, Terasaki T, Deguchi Y (2008) Involvement of the pyrilamine transporter, a putative organic cation transporter, in blood-brain barrier transport of oxycodone. Drug Metab Dispos 36:2005\u20132013","journal-title":"Drug Metab Dispos"},{"key":"879_CR15","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1089\/aid.1992.8.153","volume":"8","author":"C Debouck","year":"1992","unstructured":"Debouck C (1992) The HIV-1 protease as a therapeutic target for AIDS. AIDS Res Hum Retroviruses 8:153\u2013164","journal-title":"AIDS Res Hum Retroviruses"},{"key":"879_CR16","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1097\/00000542-199909000-00020","volume":"91","author":"KT Olkkola","year":"1999","unstructured":"Olkkola KT, Palkama VJ, Neuvonen PJ (1999) Ritonavir\u2019s role in reducing fentanyl clearance and prolonging its half-life. Anesthesiology 91:681\u2013685","journal-title":"Anesthesiology"},{"key":"879_CR17","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1016\/j.clpt.2005.09.001","volume":"78","author":"RE Aarnoutse","year":"2005","unstructured":"Aarnoutse RE, Kleinnijenhuis J, Koopmans PP, Touw DJ, Wieling J, Hekster YA, Burger DM (2005) Effect of low-dose ritonavir (100\u00a0mg twice daily) on the activity of cytochrome P450 2D6 in healthy volunteers. Clin Pharmacol Ther 78:664\u2013674","journal-title":"Clin Pharmacol Ther"},{"key":"879_CR18","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1038\/clpt.2008.102","volume":"84","author":"ED Kharasch","year":"2008","unstructured":"Kharasch ED, Bedynek PS, Walker A, Whittington D, Hoffer C (2008) Mechanism of ritonavir changes in methadone pharmacokinetics and pharmacodynamics: II. Ritonavir effects on CYP3A and P-glycoprotein activities. Clin Pharmacol Ther 84:506\u2013512","journal-title":"Clin Pharmacol Ther"},{"key":"879_CR19","doi-asserted-by":"crossref","first-page":"3617","DOI":"10.1128\/AAC.00526-07","volume":"51","author":"P Liu","year":"2007","unstructured":"Liu P, Foster G, Gandelman K, LaBadie RR, Allison MJ, Gutierrez MJ, Sharma A (2007) Steady-state pharmacokinetic and safety profiles of voriconazole and ritonavir in healthy male subjects. Antimicrob Agents Chemother 51:3617\u20133626","journal-title":"Antimicrob Agents Chemother"},{"key":"879_CR20","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1128\/AAC.01600-07","volume":"52","author":"ED Kharasch","year":"2008","unstructured":"Kharasch ED, Mitchell D, Coles R, Blanco R (2008) Rapid clinical induction of hepatic cytochrome P4502B6 activity by ritonavir. Antimicrob Agents Chemother 52:1663\u20131669","journal-title":"Antimicrob Agents Chemother"},{"key":"879_CR21","doi-asserted-by":"crossref","first-page":"275","DOI":"10.2165\/00003088-199835040-00002","volume":"35","author":"A Hsu","year":"1998","unstructured":"Hsu A, Granneman GR, Bertz RJ (1998) Ritonavir. Clinical pharmacokinetics and interactions with other anti-HIV agents. Clin Pharmacokinet 35:275\u2013291","journal-title":"Clin Pharmacokinet"},{"key":"879_CR22","doi-asserted-by":"crossref","first-page":"769","DOI":"10.2165\/00003495-200363080-00004","volume":"63","author":"RS Cvetkovic","year":"2003","unstructured":"Cvetkovic RS, Goa KL (2003) Lopinavir\/ritonavir: a review of its use in the management of HIV infection. Drugs 63:769\u2013802","journal-title":"Drugs"},{"key":"879_CR23","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1097\/01.qai.0000219774.20174.64","volume":"42","author":"RF Yeh","year":"2006","unstructured":"Yeh RF, Gaver VE, Patterson KB, Rezk NL, Baxter-Meheux F, Blake MJ, Eron JJ Jr, Klein CE, Rublein JC, Kashuba AD (2006) Lopinavir\/ritonavir induces the hepatic activity of cytochrome P450 enzymes CYP2C9, CYP2C19, and CYP1A2 but inhibits the hepatic and intestinal activity of CYP3A as measured by a phenotyping drug cocktail in healthy volunteers. J Acquir Immune Defic Syndr 42:52\u201360","journal-title":"J Acquir Immune Defic Syndr"},{"key":"879_CR24","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/sj.clpt.6100452","volume":"84","author":"C Wyen","year":"2008","unstructured":"Wyen C, Fuhr U, Frank D, Aarnoutse RE, Klaassen T, Lazar A, Seeringer A, Doroshyenko O, Kirchheiner JC, Abdulrazik F, Schmeisser N, Lehmann C, Hein W, Schomig E, Burger DM, Fatkenheuer G, Jetter A (2008) Effect of an antiretroviral regimen containing ritonavir boosted lopinavir on intestinal and hepatic CYP3A, CYP2D6 and P-glycoprotein in HIV-infected patients. Clin Pharmacol Ther 84:75\u201382","journal-title":"Clin Pharmacol Ther"},{"key":"879_CR25","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s00228-008-0568-5","volume":"65","author":"NM Hagelberg","year":"2009","unstructured":"Hagelberg NM, Nieminen TH, Saari TI, Neuvonen M, Neuvonen PJ, Laine K, Olkkola KT (2009) Voriconazole drastically increases exposure to oral oxycodone. Eur J Clin Pharmacol 65:263\u2013271","journal-title":"Eur J Clin Pharmacol"},{"key":"879_CR26","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1007\/s00228-009-0775-8","volume":"66","author":"TI Saari","year":"2010","unstructured":"Saari TI, Gr\u00f6nlund J, Hagelberg NM, Neuvonen M, Laine K, Neuvonen PJ, Olkkola KT (2010) Effects of itraconazole on the pharmacokinetics and pharmacodynamics of intravenously and orally administered oxycodone. Eur J Clin Pharmacol 66:387\u2013397","journal-title":"Eur J Clin Pharmacol"},{"key":"879_CR27","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1177\/0091270009336444","volume":"50","author":"J Gr\u00f6nlund","year":"2010","unstructured":"Gr\u00f6nlund J, Saari T, Hagelberg N, Martikainen IK, Neuvonen PJ, Olkkola KT, Laine K (2010) Effect of telithromycin on the pharmacokinetics and pharmacodynamics of oral oxycodone. J Clin Pharmacol 50:101\u2013108","journal-title":"J Clin Pharmacol"},{"key":"879_CR28","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.jpainsymman.2004.04.007","volume":"28","author":"E Michna","year":"2004","unstructured":"Michna E, Ross EL, Hynes WL, Nedeljkovic SS, Soumekh S, Janfaza D, Palombi D, Jamison RN (2004) Predicting aberrant drug behavior in patients treated for chronic pain: importance of abuse history. J Pain Symptom Manage 28:250\u2013258","journal-title":"J Pain Symptom Manage"},{"key":"879_CR29","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1373\/clinchem.2004.046466","volume":"51","author":"J Sistonen","year":"2005","unstructured":"Sistonen J, Fuselli S, Levo A, Sajantila A (2005) CYP2D6 genotyping by a multiplex primer extension reaction. Clin Chem 51:1291\u20131295","journal-title":"Clin Chem"},{"key":"879_CR30","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1097\/FTD.0b013e31816e2d4b","volume":"30","author":"M Neuvonen","year":"2008","unstructured":"Neuvonen M, Neuvonen PJ (2008) Determination of oxycodone, noroxycodone, oxymorphone, and noroxymorphone in human plasma by liquid chromatography-electrospray-tandem mass spectrometry. Ther Drug Monit 30:333\u2013340","journal-title":"Ther Drug Monit"},{"key":"879_CR31","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1016\/j.talanta.2009.06.005","volume":"79","author":"NL Rezk","year":"2009","unstructured":"Rezk NL, White NR, Jennings SH, Kashuba AD (2009) A novel LC-ESI-MS method for the simultaneous determination of etravirine, darunavir and ritonavir in human blood plasma. Talanta 79:1372\u20131378","journal-title":"Talanta"},{"key":"879_CR32","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1097\/ALN.0b013e31819faa54","volume":"110","author":"TH Nieminen","year":"2009","unstructured":"Nieminen TH, Hagelberg NM, Saari TI, Pertovaara A, Neuvonen M, Laine K, Neuvonen PJ, Olkkola KT (2009) Rifampin greatly reduces the plasma concentrations of intravenous and oral oxycodone. Anesthesiology 110:1371\u20131378","journal-title":"Anesthesiology"},{"key":"879_CR33","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1111\/j.2044-8341.1974.tb02285.x","volume":"47","author":"AJ Bond","year":"1974","unstructured":"Bond AJ, Lader MH (1974) The use of analoque scales in rating subjective feelings. Br J Med Psychol 47:211\u2013218","journal-title":"Br J Med Psychol"},{"key":"879_CR34","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1136\/bmj.3.5715.132","volume":"3","author":"JG Hannington-Kiff","year":"1970","unstructured":"Hannington-Kiff JG (1970) Measurement of recovery from outpatient general anaesthesia with a simple ocular test. Br Med J 3:132\u2013135","journal-title":"Br Med J"},{"key":"879_CR35","doi-asserted-by":"crossref","first-page":"15S","DOI":"10.1111\/j.1365-2125.1984.tb02578.x","volume":"18","author":"BM Stone","year":"1984","unstructured":"Stone BM (1984) Pencil and paper tests\u2014sensitivity to psychotropic drugs. Br J Clin Pharmacol 18:15S\u201320S","journal-title":"Br J Clin Pharmacol"},{"key":"879_CR36","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1016\/S0002-9394(14)77456-2","volume":"24","author":"DG Cogan","year":"1941","unstructured":"Cogan DG (1941) Simplifiied entoptic pupillometer. Am J Ophthalmol 24:1431\u20131433","journal-title":"Am J Ophthalmol"},{"key":"879_CR37","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/0304-3959(88)90156-X","volume":"34","author":"SF Jones","year":"1988","unstructured":"Jones SF, McQuay HJ, Moore RA, Hand CW (1988) Morphine and ibuprofen compared using the cold pressor test. Pain 34:117\u2013122","journal-title":"Pain"},{"key":"879_CR38","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1124\/jpet.104.075416","volume":"312","author":"CS Ernest 2nd","year":"2005","unstructured":"Ernest CS 2nd, Hall SD, Jones DR (2005) Mechanism-based inactivation of CYP3A by HIV protease inhibitors. J Pharmacol Exp Ther 312:583\u2013591","journal-title":"J Pharmacol Exp Ther"},{"key":"879_CR39","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1111\/j.1742-7843.2006.pto_249.x","volume":"98","author":"MT Granfors","year":"2006","unstructured":"Granfors MT, Wang JS, Kajosaari LI, Laitila J, Neuvonen PJ, Backman JT (2006) Differential inhibition of cytochrome P450 3A4, 3A5 and 3A7 by five human immunodeficiency virus (HIV) protease inhibitors in vitro. Basic Clin Pharmacol Toxicol 98:79\u201385","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"879_CR40","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1067\/mcp.2000.105757","volume":"67","author":"DJ Greenblatt","year":"2000","unstructured":"Greenblatt DJ, von Moltke LL, Harmatz JS, Durol AL, Daily JP, Graf JA, Mertzanis P, Hoffman JL, Shader RI (2000) Alprazolam-ritonavir interaction: implications for product labeling. Clin Pharmacol Ther 67:335\u2013341","journal-title":"Clin Pharmacol Ther"},{"key":"879_CR41","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S0009-9236(98)90065-0","volume":"64","author":"D Ouellet","year":"1998","unstructured":"Ouellet D, Hsu A, Granneman GR, Carlson G, Cavanaugh J, Guenther H, Leonard JM (1998) Pharmacokinetic interaction between ritonavir and clarithromycin. Clin Pharmacol Ther 64:355\u2013362","journal-title":"Clin Pharmacol Ther"},{"key":"879_CR42","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1128\/AAC.41.5.898","volume":"41","author":"A Hsu","year":"1997","unstructured":"Hsu A, Granneman GR, Witt G, Locke C, Denissen J, Molla A, Valdes J, Smith J, Erdman K, Lyons N, Niu P, Decourt JP, Fourtillan JB, Girault J, Leonard JM (1997) Multiple-dose pharmacokinetics of ritonavir in human immunodeficiency virus-infected subjects. Antimicrob Agents Chemother 41:898\u2013905","journal-title":"Antimicrob Agents Chemother"},{"key":"879_CR43","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1097\/ALN.0b013e3181986a9a","volume":"110","author":"ED Kharasch","year":"2009","unstructured":"Kharasch ED, Hoffer C, Whittington D, Walker A, Bedynek PS (2009) Methadone pharmacokinetics are independent of cytochrome P4503A (CYP3A) activity and gastrointestinal drug transport: insights from methadone interactions with ritonavir\/indinavir. Anesthesiology 110:660\u2013672","journal-title":"Anesthesiology"},{"key":"879_CR44","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1211\/002235702739","volume":"55","author":"JL Weemhoff","year":"2003","unstructured":"Weemhoff JL, von Moltke LL, Richert C, Hesse LM, Harmatz JS, Greenblatt DJ (2003) Apparent mechanism-based inhibition of human CYP3A in-vitro by lopinavir. J Pharm Pharmacol 55:381\u2013386","journal-title":"J Pharm Pharmacol"},{"key":"879_CR45","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/S0022-3565(25)12840-1","volume":"277","author":"GN Kumar","year":"1996","unstructured":"Kumar GN, Rodrigues AD, Buko AM, Denissen JF (1996) Cytochrome P450-mediated metabolism of the HIV-1 protease inhibitor ritonavir (ABT-538) in human liver microsomes. J Pharmacol Exp Ther 277:423\u2013431","journal-title":"J Pharmacol Exp Ther"},{"key":"879_CR46","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1111\/j.1399-6576.2009.02104.x","volume":"54","author":"ST Zwisler","year":"2010","unstructured":"Zwisler ST, Enggaard TP, Mikkelsen S, Brosen K, Sindrup SH (2010) Impact of the CYP2D6 genotype on post-operative intravenous oxycodone analgesia. Acta Anaesthesiol Scand 54:232\u2013240","journal-title":"Acta Anaesthesiol Scand"},{"key":"879_CR47","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.drugalcdep.2009.07.007","volume":"105","author":"RD Bruce","year":"2009","unstructured":"Bruce RD, Altice FL, Moody DE, Lin SN, Fang WB, Sabo JP, Wruck JM, Piliero PJ, Conner C, Andrews L, Friedland GH (2009) Pharmacokinetic interactions between buprenorphine\/naloxone and tipranavir\/ritonavir in HIV-negative subjects chronically receiving buprenorphine\/naloxone. Drug Alcohol Depend 105:234\u2013239","journal-title":"Drug Alcohol Depend"},{"key":"879_CR48","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.clpt.2006.04.014","volume":"80","author":"MJ Lee van der","year":"2006","unstructured":"van der Lee MJ, Dawood L, ter Hofstede HJ, de Graaff-Teulen MJ, van Ewijk-Beneken Kolmer EW, Caliskan-Yassen N, Koopmans PP, Burger DM (2006) Lopinavir\/ritonavir reduces lamotrigine plasma concentrations in healthy subjects. Clin Pharmacol Ther 80:159\u2013168","journal-title":"Clin Pharmacol Ther"},{"key":"879_CR49","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.clpt.2006.01.009","volume":"79","author":"B Lalovic","year":"2006","unstructured":"Lalovic B, Kharasch E, Hoffer C, Risler L, Liu-Chen LY, Shen DD (2006) Pharmacokinetics and pharmacodynamics of oral oxycodone in healthy human subjects: role of circulating active metabolites. Clin Pharmacol Ther 79:461\u2013479","journal-title":"Clin Pharmacol Ther"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-010-0879-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00228-010-0879-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-010-0879-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,23]],"date-time":"2025-02-23T23:34:52Z","timestamp":1740353692000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00228-010-0879-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,8,10]]},"references-count":49,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2010,10]]}},"alternative-id":["879"],"URL":"https:\/\/doi.org\/10.1007\/s00228-010-0879-1","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,8,10]]}}}